Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2021

01-12-2021 | Breast Cancer | Research article

The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis

Authors: Masoumeh Moslemi, Yousef Moradi, Hojat Dehghanbanadaki, Hamed Afkhami, Mansoor Khaledi, Najmeh Sedighimehr, Javad Fathi, Ehsan Sohrabi

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Ataxia telangiectasia-mutated (ATM) gene contributes to repair damaged DNA and to regulate cell cycle; therefore, ATM variants seem to increase breast cancer risk; however, the results are controversial. So we conducted a systematic review and meta-analysis to clarify the pooled association between various ATM variants and the risk of breast cancer.

Methods

The relevant studies were searched through Scopus, Web of Science, PubMed and Cochrane. Stratified and subgroup analyses were performed to explore heterogeneity between studies and assess effects of study quality. The pooled estimates logarithm with standard error logarithm of odds ratio and relative risk with confidence interval were calculated.

Results

This study revealed that there is association between ATM variants and the risk of breast cancer; according to the seven adjusted case-control studies, OR of this association was estimated as 1.67 (95%CI: 0.73–3.82), according to nine unadjusted case-control studies, the crude OR was 2.27 (95% CI: 1.17–4.40) and according to two cohorts, the RR was estimated as 1.68 (95% CI: 1.17–2.40).

Conclusions

The ATM variants are associated with an increased risk of breast cancer that ATM V2424G mutation is detected as the most predisposing factor while ATM D1853V, L546V, and S707P variants have the least predictive ability.
Literature
1.
Moslemi, M., et al., Expression analysis of EEPD1 and MUS81 genes in breast Cancer. 2020.
2.
Määttä K, et al. Whole-exome sequencing of Finnish hereditary breast cancer families. Eur J Hum Genet. 2017;25(1):85.CrossRef
3.
Thorstenson YR, et al. Contributions of ATM mutations to familial breast and ovarian cancer. Cancer Res. 2003;63(12):3325–33.PubMed
4.
Hirsch AE, Atencio DP, Rosenstein BS. Screening for ATM sequence alterations in African-American women diagnosed with breast cancer. Breast Cancer Res Treat. 2008;107(1):139–44.PubMedCrossRef
5.
Desmond A, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 2015;1(7):943–51.PubMedCrossRef
6.
Buys SS, et al. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes. Cancer. 2017;123(10):1721–30.PubMedCrossRef
7.
Dörk T, et al. Spectrum of ATM gene mutations in a hospital-based series of unselected breast cancer patients. Cancer Res. 2001;61(20):7608–15.PubMed
8.
Savitsky K, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268(5218):1749–53.PubMedCrossRef
9.
Bernstein J, et al. Population-based estimates of breast cancer risks associated with ATM gene variants c. 7271T> G and c. 1066–6T> G (IVS10–6T> G) from the breast Cancer family registry. Hum Mutat. 2006;27(11):1122–8.PubMedCrossRef
10.
Abraham RT. PI 3-kinase related kinases:‘big’players in stress-induced signaling pathways. DNA repair. 2004;3(8–9):883–7.PubMedCrossRef
11.
Dombernowsky SL, et al. Risk of cancer by ATM missense mutations in the general population. J Clin Oncol. 2008;26(18):3057–62.PubMedCrossRef
12.
Bogdanova, N., et al., A nonsense mutation (E1978X) in the gene is associated with breast cancer. 2008.
13.
Swift M, et al. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987;316(21):1289–94.PubMedCrossRef
14.
Chen J, et al. The role of ataxia-telangiectasia heterozygotes in familial breast cancer. Cancer Res. 1998;58(7):1376–9.PubMed
15.
16.
17.
Athma P, Rappaport R, Swift M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet. 1996;92(2):130–4.PubMedCrossRef
18.
19.
Fletcher O, et al. Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Prev Biomarkers. 2010;19(9):2143–51.CrossRef
20.
Thompson D, et al. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst. 2005;97(11):813–22.PubMedCrossRef
21.
Broeks A, et al. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat. 2008;107(2):243–8.PubMedCrossRef
22.
Hutton B, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.PubMedCrossRef
23.
Margulis AV, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa scale and the RTI item bank. Clin Epidemiol. 2014;6:359.PubMedPubMedCentralCrossRef
24.
25.
Schmidt FL, Hunter J. General mental ability in the world of work: occupational attainment and job performance. J Pers Soc Psychol. 2004;86(1):162.PubMedCrossRef
26.
Schmidt FL, Oh IS, Hayes TL. Fixed-versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62(1):97–128.PubMedCrossRef
27.
Higgins J, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.CrossRefPubMed
28.
Egger M, Smith GD, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1998;316(7129):470–1.
29.
30.
Southey MC, et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016;53(12):800–11.PubMedCrossRef
31.
Gatti RA, Tward A, Concannon P. Cancer risk in ATM heterozygotes: a model of phenotypic and mechanistic differences between missense and truncating mutations. Mol Genet Metab. 1999;68(4):419–23.PubMedCrossRef
32.
33.
van Os N, et al. Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. Clin Genet. 2016;90(2):105–17.PubMedCrossRef
34.
Marabelli M, Cheng SC, Parmigiani G. Penetrance of ATM gene mutations in breast cancer: a meta-analysis of different measures of risk. Genet Epidemiol. 2016;40(5):425–31.PubMedPubMedCentralCrossRef
35.
36.
Mitui M, et al. Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk. Hum Mutat. 2009;30(1):12–21.PubMedPubMedCentralCrossRef
37.
Gao L-B, et al. The association between ATM D1853N polymorphism and breast cancer susceptibility: a meta-analysis. J Exp Clin Cancer Res. 2010;29(1):117.PubMedPubMedCentralCrossRef
38.
Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
39.
Porter PL. Global trends in breast cancer incidence and mortality. Salud Publica Mex. 2009;51:s141–6.PubMedCrossRef
Metadata
Title
The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis
Authors
Masoumeh Moslemi
Yousef Moradi
Hojat Dehghanbanadaki
Hamed Afkhami
Mansoor Khaledi
Najmeh Sedighimehr
Javad Fathi
Ehsan Sohrabi
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07749-6

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue

Research article

Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma

Research

Prognostic value of metabolic activity of the psoas muscle evaluated by preoperative 18F-FDG PET-CT in breast cancer: a retrospective cross-sectional study

Research

Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors

Research article

Clinical utility of complex assessment with evoked potentials in acute lymphoblastic leukemia survivors: comparison of various treatment protocols

Research article

A geospatiotemporal and causal inference epidemiological exploration of substance and cannabinoid exposure as drivers of rising US pediatric cancer rates

Research

Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits